NET Cancer Awareness in November

Posted: November 10, 2016 | Word Count: 936
Please Sign In or Sign Up to download this article.

An estimated 112,000 Americans are currently living with gastrointestinal and pancreatic neuroendocrine tumors1,2, a rare and serious form of cancer.3

NET Cancer Day is an annual observance devoted to raising awareness of neuroendocrine cancer, coordinated by the International Neuroendocrine Cancer Alliance (INCA).

NETs are rare tumors formed from cells that have roles in both the endocrine and nervous system, found commonly in the gastrointestinal system.4 NETs can remain undiagnosed for years due to vague abdominal symptoms that can be attributed to other conditions.5 An estimated 112,000 Americans are currently living with gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs).1,2

Dr. Eric H. Liu of the Rocky Mountain Cancer Centers and Chief Medical Advisor, Healing NET Foundation, explained, “Raising awareness for NETs is extremely important. Both patients and doctors need increased understanding of this disease and the importance of receiving early treatment.”

Approximately 35% of NET patients consult with more than 4 doctors to determine the cause of their symptoms before being accurately diagnosed.6

“Early detection of neuroendocrine tumors is a priority because it may lead to more successful treatment outcomes. Together with the availability of treatment options and increased disease awareness, doctors and patients can be better equipped to fight neuroendocrine cancer,” said Dr. Liu.

A current treatment option for adults with GEP-NETs that have spread or cannot be removed by surgery is Somatuline® Depot (lanreotide) injection 120 mg from Ipsen Biopharmaceuticals, Inc. Compared with placebo, the chance of neuroendocrine cancer spreading or growing was lowered by 53% over a 22-month period with Somatuline Depot.7

Somatuline Depot is a synthetic version of a hormone called somatostatin, which is found naturally in the human body. It has been shown to slow tumor growth in patients, an exciting advancement in the treatment of neuroendocrine tumors.

Over the last 30 years, the incidence and prevalence of neuroendocrine tumors have risen 4-6 fold, due in large part to the ability to better test for and diagnosis the disease.8

To learn more about NETs and NET Cancer Day, please visit Consult your doctor and visit to learn more about Somatuline Depot.


Who should not take SOMATULINE DEPOT?

Do not take SOMATULINE DEPOT if you are allergic to lanreotide.

What are the possible side effects of SOMATULINE DEPOT?

SOMATULINE DEPOT may cause serious side effects, including:

  • Tell your healthcare professional if you get any of these symptoms:
    • sudden pain in your upper right stomach area (abdomen)
    • sudden pain in your right shoulder or between your shoulder blades
    • yellowing of your skin and whites of your eyes
    • fever with chills
    • nausea
  • Changes in your blood sugar(high blood sugar or low blood sugar). If you have diabetes, test your blood sugar as your healthcare professional tells you to. Your healthcare professional may change your dose of diabetes medicine.
  • Slow heart rate
  • High blood pressure

The most common side effects of SOMATULINE DEPOT in people with GEP-NETs include stomach area (abdominal) pain, muscle and joint aches, vomiting, headache, and pain, itching, or a lump at the injection site.

SOMATULINE DEPOT may cause dizziness. If this happens, do not drive a car or operate machinery.

What should I tell my healthcare professional before receiving SOMATULINE DEPOT?

  • Tell your healthcare professional if you have diabetes or gallbladder, thyroid, heart, kidney, or liver problems.
  • Tell your healthcare professional if you are pregnant or plan to become pregnant as SOMATULINE DEPOT may harm your unborn baby. Tell your healthcare professional if you are breastfeeding or plan to breastfeed. It is not known if SOMATULINE DEPOT passes into your breast milk. You and your healthcare professional should decide if you will take SOMATULINE DEPOT or breastfeed. You should not do both.
  • Tell your healthcare professional about all the medicines you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOMATULINE DEPOT and other medicines may affect each other, causing side effects. SOMATULINE DEPOT may affect the way other medicines work, and other medicines may affect how SOMATULINE DEPOT works.
  • Especially tell your healthcare professional if you take insulin or other diabetes medicines, a cyclosporine (Gengraf, Neoral, or Sandimmune), a medicine called bromocriptine (Parlodel, Cycloset), or medicines that lower your heart rate, such as beta blockers.

Tell your healthcare professional if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of SOMATULINE DEPOT. For more information, ask your healthcare professional.

You may report side effects to FDA at 1-800-FDA-1088 or Ipsen Biopharmaceuticals, Inc. at 1-888-980-2889.

Please click here for Patient Information and full Prescribing Information.

Somatuline DEPOT is a registered trademark of IPSEN PHARMA S.A.S.

All other trademarks are the property of their respective owners.


  1. O¨berg, K, Knigge, U, Kwekkeboom, D, Perren, A, (2012). Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(Supplement 7), 124-130.
  2. United States Census Bureau. Census Website. Accessed October 19, 2016.
  3. Neuroendocrine Tumor. American Society of Clinical Oncology Conquer Cancer Foundation Website: Accessed October 19, 2016.
  4. American Cancer Society. Detailed guide. Gastrointestinal carcinoid tumors. What is it? Available at: Accessed October 19, 2016.
  5. Claxton, W, Poon, D. (2010). Carcinoid & Neuroendocrine Tumor Society of Singapore (CNETS)Survey on Delaying Diagnosis of Neuroendocrine Tumors [Abstract]. Presented at 35th Congress of the European Society for Medical Oncology.
  6. NCAN Survey Results on file*
  7. Caplin, M., Pavel, M., Cwikla, J.B., Phan, A.T., Raderer, M., Sedlácková, E., Cadiot, G., Wolin, E.M., Capdevila, J., Wall, L., Rindi, G., Langley, A., Martinez, S., Blumberg, J., Ruszniewski, P. (2014). Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. The New England Journal of Medicine, 371, 224-233.

*These statistics are based on a survey initiated by the Neuroendocrine Cancer Awareness Network, in partnership with Ipsen Biopharmaceuticals, Inc. The survey was conducted by Wakefield Research and received responses from 265 U.S adults being treated for neuroendocrine tumors between July 11th and August 13th, 2015.

November 2016 SMD-US-000892 v2

 Upload a Clip

Get Our Newsletter

Sign up for our newsletter to keep up-to-date on the latest content.

Bradnpoint logo
© 2016 Brandpoint - All Rights Reserved.